Pathology & Oncology Research最新文献

{"title":"Immunohistochemistry-based molecular subtyping of triple-negative breast cancer and its prognostic significance.","authors":"Marisa Leeha,&nbsp;Kanyanatt Kanokwiroon,&nbsp;Suphawat Laohawiriyakamol,&nbsp;Paramee Thongsuksai","doi":"10.3389/pore.2023.1611162","DOIUrl":"https://doi.org/10.3389/pore.2023.1611162","url":null,"abstract":"<p><p><b>Background:</b> Immunohistochemistry (IHC)-based protein markers representing molecular subtypes are of great value for routine use. This study aimed to evaluate the frequency distributions of the molecular subtypes of triple-negative breast cancer (TNBC) using IHC-based surrogate markers and examined their prognostic value. <b>Methods:</b> Patients with TNBC treated at a university hospital in Southern Thailand were included in this study. Expression levels of androgen receptor, CD8, Forkhead box transcription factor C1, and Doublecortin-like kinase 1 were detected in tumor tissue to classify them into luminal androgen receptor (LAR), immunomodulatory (IM), basal-like immunosuppressed (BLIS), mesenchymal-like (MES), and unclassifiable (UC) subtypes. The association between variables and disease-free survival (DFS) and overall survival (OS) was analyzed using Cox proportional hazards regression. <b>Results:</b> Among the 195 cases of TNBC, the frequency distribution of the IHC-based subtype was as follows: BLIS, 52.8%; LAR, 19.0%; IM, 17.4%; MES, 0.5%; and un-classifiable, 10.3%. BLIS subtype was significantly found in younger ages (mean: 49.6 years) than other subtypes (mean: 51-57.7 years). LAR and BLIS subtypes were significantly associated with poorer OS compared to the IM subtype in univariate analysis, however, only BLIS was significant in multivariate analysis (HR: 3.29, 95% CI: 1.01-10.72). IHC-based subtype was not found to be associated with DFS. <b>Conclusion:</b> This study revealed the differences in the proportion frequency of IHC-based TNBC subtypes in Thai patients compared to other populations. IHC-based molecular subtyping may be beneficial for prognosis. However further refinement of the molecular classification of TNBC is needed for better clinical relevance.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10235452/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9637306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Report: Brainstem angiocentric glioma presenting in a toddler child-diagnostic and therapeutic challenges.","authors":"Zita Reisz,&nbsp;Bence Laszlo Radics,&nbsp;Peter Nemes,&nbsp;Ross Laxton,&nbsp;Laszlo Kaizer,&nbsp;Krisztina Mita Gabor,&nbsp;Timea Novak,&nbsp;Pal Barzo,&nbsp;Safa Al-Sarraj,&nbsp;Istvan Bodi","doi":"10.3389/pore.2023.1611231","DOIUrl":"https://doi.org/10.3389/pore.2023.1611231","url":null,"abstract":"<p><p><b>Introduction:</b> Angiocentric gliomas (AG) in brainstem location are exceedingly rare and might cause differential diagnostic problems and uncertainty regarding the best therapeutic approach. Hereby, we describe the clinicopathological findings in a brainstem AG presenting in a toddler child and review the literature. <b>Case report:</b> A 2-year-old boy presented with 5 weeks history of gait disturbances, frequent falls, left-sided torticollis and swallowing problems. MRI head showed a T2-hyperintense, partly exophytic mass lesion centred in the pontomedullary region, raising the possibility of diffuse midline glioma. The exophytic component was partially resected by suboccipital craniotomy, leaving intact the infiltrative component. Ventriculoperitoneal shunt was implanted due to postoperative hydrocephalus. Histological examination revealed a moderately cellular tumour consisted of bland glial cells infiltrating the brain parenchyma and radially arranged around the blood vessels. By immunohistochemistry, the tumour strongly expressed S100 and GFAP in addition to intense nestin positivity, while OLIG2 was negative in the perivascular tumour cells. DNA methylation array profiled the tumour as \"methylation class diffuse astrocytoma, <i>MYB</i> or <i>MYBL1</i>-altered subtype B (infratentorial)\" and an in-frame <i>MYB::QKI</i> fusion was identified by RNA sequencing, confirming the diagnosis of angiocentric glioma. The patient has been initially treated with angiogenesis inhibitor and mTOR inhibitor, and now he is receiving palliative vinblastine. He is clinically stable on 9 months follow-up. <b>Conclusion:</b> Brainstem AG may cause a diagnostic problem, and the surgical and oncological management is challenging due to unresectability and lack of response to conventional chemo-radiation. In the future, genetically-tailored therapies might improve the prognosis.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10287963/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10075331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Screening of core genes and prediction of ceRNA regulation mechanism of circRNAs in nasopharyngeal carcinoma by bioinformatics analysis.","authors":"HongMin Chen,&nbsp;XiaoXiao Shi,&nbsp;Li Ren,&nbsp;YuMing Wan,&nbsp;HongYu Zhuo,&nbsp;Li Zeng,&nbsp;WangMu SangDan,&nbsp;Feng Wang","doi":"10.3389/pore.2023.1610960","DOIUrl":"https://doi.org/10.3389/pore.2023.1610960","url":null,"abstract":"<p><p><b>Background:</b> Nasopharyngeal carcinoma (NPC) represents a highly aggressive malignant tumor. Competing endogenous RNAs (ceRNA) regulation is a common regulatory mechanism in tumors. The ceRNA network links the functions between mRNAs and ncRNAs, thus playing an important regulatory role in diseases. This study screened the potential key genes in NPC and predicted regulatory mechanisms using bioinformatics analysis. <b>Methods:</b> The merged microarray data of three NPC-related mRNA expression microarrays from the Gene Expression Omnibus (GEO) database and the expression data of tumor samples or normal samples from the nasopharynx and tonsil in The Cancer Genome Atlas (TCGA) database were both subjected to differential analysis and Weighted Gene Co-expression Network Analysis (WGCNA). The results from two different databases were intersected with WGCNA results to obtain potential regulatory genes in NPC, followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional enrichment analyses. The hub-gene in candidate genes was discerned through Protein-Protein Interaction (PPI) analysis and its upstream regulatory mechanism was predicted by miRwalk and circbank databases. <b>Results:</b> Totally 68 upregulated genes and 96 downregulated genes in NPC were screened through GEO and TCGA. According to WGCNA, the NPC-related modules were screened from GEO and TCGA analysis results, and the genes in the modules were obtained. After the results of differential analysis and WGCNA were intersected, 74 differentially expressed candidate genes associated with NPC were discerned. Finally, fibronectin 1 (FN1) was identified as a hub-gene in NPC. Prediction of upstream regulatory mechanisms of FN1 suggested that FN1 may be regulated by ceRNA mechanisms involving multiple circRNAs, thereby influencing NPC progression through ceRNA regulation. <b>Conclusion:</b> FN1 is identified as a key regulator in NPC development and is likely to be regulated by numerous circRNA-mediated ceRNA mechanisms.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086187/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9302893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression of aquaporin 1, 3 and 5 in colorectal carcinoma: correlation with clinicopathological characteristics and prognosis.","authors":"Guangwen Zhang,&nbsp;Yongfei Hao,&nbsp;Ling Chen,&nbsp;Zengshan Li,&nbsp;Langlang Gao,&nbsp;Jian Tian,&nbsp;Qing Qiao,&nbsp;Jinsong Zhang","doi":"10.3389/pore.2023.1611179","DOIUrl":"https://doi.org/10.3389/pore.2023.1611179","url":null,"abstract":"<p><p><b>Background:</b> Prognostic biomarkers in colorectal carcinoma (CRC) have an important role in therapeutic strategy. Studies have shown that high expression of Aquaporin (AQP) is associated with poor prognosis in a variety of human tumors. AQP is involved in the initiation and development of CRC. The present study aimed to investigate the correlation between the expression of AQP1, 3 and 5 and clinicopathological features or prognosis in CRC. <b>Methods:</b> The AQP1, 3 and 5 expressions were analyzed based on the immunohistochemical staining of tissue microarray specimens including 112 patients with CRC between June 2006 and November 2008. The expression score of AQP (Allred_score and H_score) was digitally obtained with Qupath software. Patients were divided into high or low expression subgroups based on the optimal cut-off values. The relationship between expression of AQP and clinicopathological characteristics were evaluated using chi-square test, t-test, or one-way ANOVA, when appropriate. Survival analysis of 5-year progression free survival (PFS) and overall survival (OS) was performed with time-dependent ROC, Kaplan-Meier curves, univariate and multivariate COX analysis. <b>Results:</b> The AQP1, 3 and 5 expressions were associated with regional lymph node metastasis, histological grading, and tumor location in CRC, respectively (<i>p</i> < 0.05). Kaplan-Meier curves showed that patients with high AQP1 expression had worse 5-year PFS than those with low AQP1 expression (Allred_score: 47% vs. 72%, <i>p</i> = 0.015; H_score: 52% vs. 78% <i>p</i> = 0.006), as well as 5-year OS (Allred_score: 51% vs. 75%, <i>p</i> = 0.005; H_score: 56% vs. 80%, <i>p</i> = 0.002). Multivariate Cox regression analysis indicated that AQP1 expression was an independent risk prognostic factor (<i>p</i> = 0.033, HR = 2.274, HR95% CI: 1.069-4.836). There was no significant correlation between the expression of AQP3 and 5 and the prognosis. <b>Conclusion:</b> The AQP1, 3 and 5 expressions correlate with different clinicopathological characteristics and the AQP1 expression may be a potential biomarker of prognosis in CRC.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272351/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9654454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of the low dose apatinib plus deep hyperthermia as third-line or later treatment in HER-2 negative advanced gastric cancer.","authors":"Guohu Han,&nbsp;Changchun Sun,&nbsp;Lihua Cui,&nbsp;Yufeng Huang,&nbsp;Lijiang Yu,&nbsp;Shenzha Liu,&nbsp;Min Tao","doi":"10.3389/pore.2023.1611114","DOIUrl":"https://doi.org/10.3389/pore.2023.1611114","url":null,"abstract":"<p><p><b>Aim:</b> To observe the efficacy of the low dose apatinib plus deep hyperthermia as third-line or later treatment for patients with human epidermal growth factor receptor 2 (HER-2) negative advanced gastric cancer. <b>Methods:</b> 80 eligible patients with HER-2 negative advanced gastric cancer admitted to Jingjiang People's Hospital Affiliated with Yangzhou University-from March 2021 to March 2022 were selected, and they were divided into the control group (<i>n</i> = 40, apatinib) and experimental group (<i>n</i> = 40, apatinib plus deep hyperthermia) on the basis of random number table method. The levels of serum carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA199), and vascular endothelial growth factor (VEGF) were monitored, and the efficacy of the two groups was analyzed by referring to Karnofsky performance status (KPS), overall survival (OS) and disease control rate (DCR) before and after treatment. <b>Results:</b> The levels of CEA, CA199, and VEGF in both groups were lower after treatment than before (<i>p</i> < 0.05), and lower (CEA: 8.85 ± 1.36 vs. 12.87 ± 1.23, CA199: 34.19 ± 4.68 vs. 50.11 ± 5.73, VEGF: 124.8 ± 18.03 vs. 205.9 ± 19.91) in the experimental group than in the control group (<i>p</i> < 0.05). The DCR and KPS of the patients in the experimental group were significantly higher (DCR: 62.50% vs. 40.00%; KPS: 83.25 ± 1.15 vs. 76.25 ± 1.17) than in the control group (<i>p</i> < 0.05). In survival analysis, patients with control group had shorter OS than the experimental group. (median 5.65 vs. 6.50 months; hazard ratio [HR], 1.63 [95% confidence interval (CI) 1.02-2.60], <i>p</i> = 0.0396). <b>Conclusion:</b> The application of low-dose apatinib plus deep hyperthermia for patients with HER-2 negative gastric cancer who failed second-line treatment should be a promising option.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10350525/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9847142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case report: Circulating tumor DNA technology displays temporal and spatial heterogeneity in Waldenström macroglobulinemia during treatment with <i>BTK</i> inhibitors.","authors":"Jingjing Zhu,&nbsp;Xinyu Zhu,&nbsp;Fengyang Xie,&nbsp;Yi Ding,&nbsp;Huina Lu,&nbsp;Yan Dong,&nbsp;Ping Li,&nbsp;Jianfei Fu,&nbsp;Aibin Liang,&nbsp;Yu Zeng,&nbsp;Bing Xiu","doi":"10.3389/pore.2023.1611070","DOIUrl":"https://doi.org/10.3389/pore.2023.1611070","url":null,"abstract":"<p><p><b>Background:</b> Waldenström macroglobulinemia (WM) is a rare subtype of B-cell lymphoma. Rituximab-based combination therapy and Bruton's tyrosine kinase (<i>BTK</i>) inhibitors have greatly improved the prognosis of WM. Despite the high response rate and good tolerance of <i>BTK</i> inhibitors in treatment of WM, a proportion of patients still experience disease progression. <b>Case presentation:</b> We report a 55-year-old man with relapsed WM. The patient achieved partial remission after six courses of CHOP chemotherapy and multiple plasma exchanges in initial treatment. He was admitted to the hospital with abdominal distension, and was diagnosed with relapsed WM and subsequently started on zanubrutinib. Disease progression and histological transformation occurred during treatment. We performed liquid biopsies on transformed plasma, tumor tissue and ascites at the same time and found high consistency between ascites and tissues. Moreover, we detected resistance mutations of <i>BTK</i> inhibitors (<i>BTK</i>, <i>PLCG2</i>) in ascites that were not detected in plasma or tissue. Eventually, the patient died during the 15-month follow-up after relapse. <b>Conclusion:</b> We describe a rare case of WM transformation to DLCBCL treated with chemoimmunotherapy and <i>BTK</i> inhibition. We analyzed tumor DNA obtained at different anatomic sites and circulating tumor DNA (ctDNA) derived from plasma and ascites specimens, with apparent significant temporal and spatial heterogeneity. The case specifically highlights the clinical value of ctDNA of ascites supernatant from WM patients, which is a more convenient and relatively noninvasive method compared with traditional invasive tissue biopsy.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154527/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9457960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of the input material quality for the production of tisagenlecleucel by multiparameter flow cytometry and its relation to the clinical outcome.","authors":"Martin Štach,&nbsp;Robert Pytlík,&nbsp;Kristýna Šmilauerová,&nbsp;Jana Rychlá,&nbsp;Martin Mucha,&nbsp;Jan Musil,&nbsp;Abhishek Koladiya,&nbsp;Matěj Nemec,&nbsp;Martina Petráčková,&nbsp;Iva Kaštánková,&nbsp;Pavla Pecherková,&nbsp;Lucie Šrámková,&nbsp;Kamila Polgárová,&nbsp;Marek Trněný,&nbsp;Petr Lesný,&nbsp;Jan Vydra,&nbsp;Pavel Otáhal","doi":"10.3389/pore.2023.1610914","DOIUrl":"https://doi.org/10.3389/pore.2023.1610914","url":null,"abstract":"<p><p>Tisagenlecleucel (tisa-cel) is a CD19^-specific CAR-T cell product approved for the treatment of relapsed/refractory (r/r) DLBCL or B-ALL. We have followed a group of patients diagnosed with childhood B-ALL (<i>n</i> = 5), adult B-ALL (<i>n</i> = 2), and DLBCL (<i>n</i> = 25) who were treated with tisa-cel under non-clinical trial conditions. The goal was to determine how the intensive pretreatment of patients affects the produced CAR-T cells, their <i>in vivo</i> expansion, and the outcome of the therapy. Multiparametric flow cytometry was used to analyze the material used for manufacturing CAR-T cells (apheresis), the CAR-T cell product itself, and blood samples obtained at three timepoints after administration. We present the analysis of memory phenotype of CD4/CD8 CAR-T lymphocytes (CD45RA, CD62L, CD27, CD28) and the expression of inhibitory receptors (PD-1, TIGIT). In addition, we show its relation to the patients' clinical characteristics, such as tumor burden and sensitivity to prior therapies. Patients who responded to therapy had a higher percentage of CD8⁺CD45RA⁺CD27⁺ T cells in the apheresis, although not in the produced CAR-Ts. Patients with primary refractory aggressive B-cell lymphomas had the poorest outcomes which was characterized by undetectable CAR-T cell expansion <i>in vivo</i>. No clear correlation of the outcome with the immunophenotypes of CAR-Ts was observed. Our results suggest that an important parameter predicting therapy efficacy is CAR-Ts' level of expansion <i>in vivo</i> but not the immunophenotype. After CAR-T cells' administration, measurements at several timepoints accurately detect their proliferation intensity <i>in vivo</i>. The outcome of CAR-T cell therapy largely depends on biological characteristics of the tumors rather than on the immunophenotype of produced CAR-Ts.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156917/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9429406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>RET</i> rearrangements are relevant to histopathologic subtypes and clinicopathological features in Thai papillary thyroid carcinoma patients.","authors":"Thitima Khonrak,&nbsp;Sasithorn Watcharadetwittaya,&nbsp;Yaovalux Chamgramol,&nbsp;Piyapharom Intarawichian,&nbsp;Raksawan Deenonpoe","doi":"10.3389/pore.2023.1611138","DOIUrl":"https://doi.org/10.3389/pore.2023.1611138","url":null,"abstract":"<p><p><b>Background:</b> Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer<i>.</i> The <i>RET</i> gene rearrangements <i>CCDC6</i>::<i>RET</i> and <i>NCOA4</i>::<i>RET</i> are the most common <i>RET</i> gene rearrangements in PTC patients. Different <i>RET</i>::<i>PTC</i> rearrangements are associated with different PTC phenotypes. <b>Methods:</b> Eighty-three formalin-fixed paraffin-embedded (FFPE) PTC samples were examined. The prevalence and expression levels of <i>CCDC6</i>::<i>RET</i> and <i>NCOA4</i>::<i>RET</i> were determined using semi-quantitative polymerase chain reaction (qRT-PCR). The association of these rearrangements with clinicopathological data was investigated. <b>Results:</b> The presence of <i>CCDC6</i>::<i>RET</i> rearrangement was significantly associated with the classic subtype and absence of angio/lymphatic invasion (<i>p</i> < 0.05). While <i>NCOA4</i>::<i>RET</i> was associated with the tall-cell subtype, and presence of angio/lymphatic invasion and lymph node metastasis (<i>p</i> < 0.05). Multivariate analysis demonstrated that an absence of extrathyroidal extension and extranodal extension were independent predictive factors for <i>CCDC6</i>::<i>RET</i>, whereas the tall-cell subtype, large tumor size, angioinvasion, lymphatic invasion and perineural invasion were independent predictive factors for <i>NCOA4</i>::<i>RET</i> (<i>p</i> < 0.05). However, the mRNA expression level of <i>CCDC6</i>::<i>RET</i> and of <i>NCOA4</i>::<i>RET</i> were not significantly associated with clinicopathological data. <b>Conclusion:</b> <i>CCDC6</i>::<i>RET</i> was correlated with an innocent PTC subtype and characteristics, but <i>NCOA4</i>::<i>RET</i> correlated with an aggressive phenotype of PTC. Therefore, these <i>RET</i> rearrangements strongly associated with clinicopathological phenotypes and can be used as predictive markers in PTC patients.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175595/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9491309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification and validation of molecular subtype and prognostic signature for lung adenocarcinoma based on neutrophil extracellular traps.","authors":"Yanhua Zuo,&nbsp;Guangyi Leng,&nbsp;Ping Leng","doi":"10.3389/pore.2023.1610899","DOIUrl":"https://doi.org/10.3389/pore.2023.1610899","url":null,"abstract":"<p><p><b>Background:</b> Neutrophil Extracellular Traps (NETs) are fibrous networks made of DNA-histone complexes and proteins protruded from activated neutrophils. Accumulating evidences have highlighted the vital role of NETs in tumor progression and diffusion. However, limited systematic studies regarding the role of NETs in LUAD have been performed. <b>Methods:</b> Differentially expressed NETs-related genes and their mutation landscape were identified with TCGA database. Consensus clustering analysis was performed to determine the NETs-related subtypes of LUAD. LASSO algorithm was employed to construct a prognostic signature. Moreover, GSE30219 and GSE31210 were used as independent validation. We also constructed a lncRNA-miRNA-mRNA regulatory axis with several miRNA and lncRNA databases. <b>Results:</b> Consensus clustering identified two NETs-related clusters in LUAD. High NETs score was correlated with a favorable overall survival, abundant immune cell infiltration, and high activity of immune response signal pathways. Six NET-related genes (G0S2, KCNJ15, S100A12, AKT2, CTSG, and HMGB1) with significant prognostic value were screened to develop a prognostic signature. LUAD patients with low-risk had a significantly favorable overall survival both in the training set and validation set. Moreover, NETs-related risk score and clinical stage could act as an independent prognostic factor for LUAD patients. Significant correlation was obtained between risk score and tumor immune microenvironment. We also identified lncRNA BCYRN1/miR-3664-5p/CTSG regulatory axis that may be involved in the progression of LUAD. <b>Conclusion:</b> We developed two molecular subtypes and a prognostic signature for LUAD based on NETs-related genes. This stratification could provide more evidences for estimating the prognosis and immunotherapy of LAUD patients.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151567/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9777453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum: Systemic treatment of breast cancer. 1st Central-Eastern European professional Consensus Statement on breast cancer.","authors":"Gábor Rubovszky,&nbsp;Judit Kocsis,&nbsp;Katalin Boér,&nbsp;Nataliya Chilingirova,&nbsp;Magdolna Dank,&nbsp;Zsuzsanna Kahán,&nbsp;Dilyara Kaidarova,&nbsp;Erika Kövér,&nbsp;Bibiana Vertáková Krakovská,&nbsp;Károly Máhr,&nbsp;Bela Mriňáková,&nbsp;Béla Pikó,&nbsp;Ivana Božović-Spasojević,&nbsp;Zsolt Horváth","doi":"10.3389/pore.2023.1610954","DOIUrl":"https://doi.org/10.3389/pore.2023.1610954","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/pore.2022.1610383.].</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9927865/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10795870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}